Management of Hemolytic Transfusion Reactions
Immediate Actions
- The American College of Cardiology is not mentioned, however, it is recommended to discontinue the blood product immediately when any signs appear: tachycardia, hypotension, fever, rash, breathlessness, or hemoglobinuria 1
- Maintain IV access with normal saline to support blood pressure and renal perfusion 1
- Contact the transfusion laboratory immediately and return the blood product with all associated documentation for investigation 1
- Double-check all documentation to identify potential administration errors, including verifying the four core identifiers (first name, last name, date of birth, patient ID number) 1
- Visually inspect the blood product for discoloration, clots, or leakage 1
Initial Pharmacologic Management
- Antihistamines for allergic symptoms (urticaria, pruritus) 1
- Steroids (methylprednisolone or prednisone) for severe reactions 1
- Intramuscular or intravenous epinephrine if the reaction is life-threatening or anaphylactic 1
- First-line immunosuppressive therapy should be initiated promptly in patients with life-threatening hemolysis 2, 3
- IVIg: 0.4-1 g/kg/day for 3-5 days (up to total dose of 2 g/kg) 2, 4, 1
- High-dose steroids: Methylprednisolone or prednisone 1-4 mg/kg/day 2, 4, 1
- Rituximab: 375 mg/m² repeated after 2 weeks, primarily indicated for prevention of additional alloantibody formation in patients requiring future transfusions 2, 4, 1
Critical Management Principle: Transfusion Avoidance
- Avoid further transfusion unless the patient is experiencing life-threatening anemia with ongoing hemolysis, as additional transfusions may worsen hemolysis and potentially induce multiorgan failure and death 2, 4
- If transfusion is absolutely warranted for life-threatening anemia, use extended matched red cells (C/c, E/e, K, Jka/Jkb, Fya/Fyb, S/s) 2, 4, 1
Supportive Care
- Erythropoietin with or without IV iron should be initiated in all patients 2, 4
- Folic acid supplementation 1 mg daily 3
Diagnostic Workup During Acute Management
- Send blood samples for repeat type and crossmatch, direct antiglobulin test (DAT), hemolysis markers (LDH, haptoglobin, bilirubin, free hemoglobin) 3
- Monitor reticulocyte count: relative reticulocytopenia suggests hyperhemolysis 2
Common Pitfalls to Avoid
- Do not transfuse additional blood in hyperhemolysis without immunosuppressive therapy, as this can exacerbate hemolysis and cause death 2, 4
- Do not delay immunosuppressive therapy in severe cases with life-threatening hemolysis, as this increases morbidity and mortality 3
- Recognize that hyperhemolysis can occur with no identifiable antibody and a negative direct antiglobulin test, making clinical recognition essential 4